Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors

Next Previous
Trial Profile

A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Endometrial cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms KEYNOTE-146; KEYNOTE-526
  • Sponsors Eisai Inc

Most Recent Events

  • 05 Jan 2024 Results focusing on Characterization and Management of Adverse Reactions ,published in the Oncologist
  • 06 Jan 2023 Updated results (data cutoff date August 18, 2020, n=108) analyzing long-term follow-up efficacy and safety data of included in the primary analysis patients with previously treated EC, published in the Journal of Clinical Oncology
  • 22 Jun 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top